Accentia Biopharmaceuticals Announces that Revimmune(TM) Autoimmune Disease Therapy is Featured in Peer-review Journal
Published: May 04, 2011
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI) today announced that Revimmune™, its proprietary system-of-care based on high-dose administration of Cytoxan® (cyclophosphamide), was featured in an article published in the peer-reviewed journal, Medicine (Volume 90, Number 2, March 2011). Accentia in-licensed Revimmune™ from Johns Hopkins University following pioneering work on the therapy by Johns Hopkins hematology and neurology faculty, including Drs. Robert Brodsky and Richard Jones. Accentia intends to advance the use of Revimmune for the treatment of a wide range of autoimmune diseases, including multiple sclerosis.